Hyper-CVAD + ponatinib vs. hyper-CVAD + dasatinib as frontline therapy for Ph-positive ALL: a propensity score analysis

BACKGROUND: The clinical efficacy of hyper-CVAD (HCVAD) + ponatinib has not been compared to that of HCVAD + dasatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in a randomized clinical trial. METHODS: We analyzed 110 patients with newly diagnosed Ph+ A...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: Sasaki, Koji, Jabbour, Elias, Ravandi, Farhad, Short, Nicholas J., Thomas, Deborah, Garcia-Manero, Guillermo, Daver, Naval, Kadia, Tapan, Konopleva, Marina, Jain, Nitin, Issa, Ghayas C., Jeanis, Vicki, Moore, Gal, Garris, Rebecca, Pemmaraju, Naveen, Cortes, Jorge E., O'Brien, Susan, Kantarjian, Hagop
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5321539/
https://ncbi.nlm.nih.gov/pubmed/27479888
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30231
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados